
|Articles|June 1, 2003
Oral Valacyclovir Option
San Francisco - A one-week course of oral valacyclovir (Valtrex) appears to be a safe, effective, and economical alternative to inpatient or outpatient intravenous (IV) acyclovir (Zovirax) for treatment of immunocompromised patients with uncomplicated, acute herpes zoster virus infections, Mathijs H. Brentjens, M.D., said at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
Dermatology Conferences and Meetings Calendar: December 2025
4
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
5


















